Texas is currently home to 4879 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Targeted Pediatric High-Grade Glioma Therapy
Recruiting
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
06/06/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
Recruiting
To compare the outcomes of and responses to 2 different radiation therapy schedules (the standard radiation amount and number of doses versus less radiation and fewer doses) that are being given before having breast cancer surgery (cancer removal and reconstruction).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Recruiting
To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Recruiting
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer, Cervical Cancer
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Recruiting
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma, Lymphoma
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
Recruiting
This phase II trial tests whether \[18F\]FluorThanatrace by positron emission tomography (PET)/computed tomography (CT) can improve imaging techniques in patients with breast cancer undergoing a standard of care biopsy or surgery. \[18F\]FluorThanatrace is a new radioactive tracer, which is a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET is an established imaging technique that utilizes small amounts of radioactivity attac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Carcinoma
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Recruiting
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized myasthenia gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Texas Institute for Neurological Disorders - Arlington, Arlington, Texas
Conditions: Generalized Myasthenia Gravis
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
Recruiting
This study examines the long-term effects of tamoxifen (TAM) treatment on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects. NET are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system. Treatment with tamoxifen increases the production of NETs. This study may help researchers determine if the increased number of NETs in the body has a damaging effect in breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Carcinoma
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Recruiting
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
Gender:
ALL
Ages:
Between 18 years and 123 years
Trial Updated:
06/06/2025
Locations: Research Site, Dallas, Texas
Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
Recruiting
This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Recruiting
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Advanced or Metastatic Solid Tumor Malignancies
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Recruiting
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/06/2025
Locations: Travere Investigational Site, Houston, Texas
Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, Alport Syndrome, IgA Vasculitis